Lorvotuzumab-MMAE, an antibody-drug conjugate (ADC), comprises a neural cell adhesion molecule (NCAM)-targeted antibody linked to Monomethyl auristatin E (MMAE), and is utilized in the research of multiple myeloma.
Target:
Others
* VAT and and shipping costs not included. Errors and price changes excepted
